Figure 1.
Figure 1. FFS and OS for patients with advanced-stage classical Hodgkin lymphoma after primary treatment with ABVD + brentuximab vedotin (ABVD+Bv) or AVD + brentuximab vedotin (AVD+Bv).

FFS and OS for patients with advanced-stage classical Hodgkin lymphoma after primary treatment with ABVD + brentuximab vedotin (ABVD+Bv) or AVD + brentuximab vedotin (AVD+Bv).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal